Data4Life and Monash Health Announce Strategic Collaboration to Advance Clinical Research
mehr
Meldungen zum Thema Gesundheit / Medizin
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich
Aachen, Germany (ots) - Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic ...
mehrGrünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy
Aachen (ots) - Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD). Tegacorat, a non-steroidal Selective Glucocorticoid ...
mehrGrünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist
Aachen (ots) - - The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain. - In a Phase I trial, the investigational compound was demonstrated to be safe and well tolerated. - A Phase II trial will commence later this year. Grünenthal announced today that the ...
mehrPromising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity
Tübingen (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced positive top-line efficacy results from its completed Phase 2a PROHEAR Study. ACOU085 is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across ...
mehrThe Virchow Prize 2026 Awarded for Pioneering Work on Ebola, Advancing Global Epidemic Preparedness and Fostering Global Solidarity
mehrLTS Lohmann Therapie-Systeme AG
LTS Expands CDMO Portfolio with Ophthalmic Drug Delivery Solutions
Andernach (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company specializing in advanced drug delivery systems, today announced the expansion of its service portfolio to include CDMO services for ophthalmic drug delivery solutions, with manufacturing capacities located in the United States at LTS’ Lakewood, New Jersey facility. The new offering focuses initially on product ...
mehrVITUS Privatklinik Prof. Dr. Stehling GmbH
First Clinical Analysis of Electrochemotherapy in Prostate Cancer Shows 93% Response
OFFENBACH, Germany (ots) - Vitus Privatklinik reports the first and largest clinical cohort of electrochemotherapy in prostate cancer. Vitus Privatklinik published the first clinical analysis of electrochemotherapy in prostate cancer, involving 144 patients treated between 2017 and 2024. The report is the largest dataset to date on this treatment. Radical prostatectomy ...
mehrFUTRUE Neurosciences Reaches Major Milestone
mehrGrünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm
Aachen, Germany & Yeoju, South Korea (ots) - Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will ...
mehr- 3
Medi-Globe Launches mAI Companion® - the World’s First Real‑Time AI Assistant for Pancreatic EUS, Co‑Developed with IHU Strasbourg / Now MDR CE‑Marked and Available for Clinical Use in Europe
mehr Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect
Aachen, Germany & Victoria, Australia (ots) - Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a ...
mehrGrünenthal’s proprietary NaV 1.8 inhibitor enters clinical development
Aachen, Germany (ots) - Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in ...
mehrGrünenthal licenses exclusive Canadian rights to testosterone replacement therapy Nebido® to Apotex
Aachen, Germany & Toronto, Canada (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to ...
mehrServier delivers solid performance in 2024/25 and confirms its forecasts for 2030
Suresnes, France (ots/PRNewswire) - - Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. - Growth over the financial year was driven by increased sales in oncology, particularly in the United States. - Several partnership agreements in oncology and neurology strengthen the Group's R&D portfolio in rare diseases. - Achieving 2025 ...
mehrSharjah Government Media Bureau
Sharjah Achieves Historic WHO Age-Friendly Status
SHARJAH, UAE (ots) - The Emirate of Sharjah, UAE, has reached a new global milestone by obtaining "Advanced Affiliate" membership in the World Health Organization’s (WHO) Global Network for Age-Friendly Cities and Communities. This makes Sharjah the first Arab city to achieve this prestigious status. This achievement underscores the emirate's deep commitment to enhancing the well-being of its senior residents and ...
mehrAcousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small ...
mehr30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength
mehrXlife Sciences AG Delivers Breakthrough in Early Alzheimer’s Detection, Unlocking Major Market Opportunity
mehrDeutsche Gesellschaft für Chirotherapie und Osteopathie e. V.
Internationally honored: Prof. Dietmar Jürgen Daichendt receives honorary doctorate for pioneering achievements in osteopathy and manual medicine
mehrAsklepios Kliniken GmbH & Co. KGaA
Hessian Minister President Boris Rhein presents the Broermann Medical Innovation Award
Wiesbaden, Germany (ots) - - Dr. Carl June and Dr. Michel Sadelain honored for groundbreaking CAR-T cell research in cancer therapy - One of the world’s most highly endowed medical prizes, with €1 million in prize money, awarded for the first time - Titia große Broermann: “With the Broermann Medical Innovation Award, we want to make outstanding medical ...
mehrEuropean Society for Medical Oncology (ESMO)
ESMO releases first-ever guidance for safe use of AI Language Models in cancer care
mehrHealth is a Political Choice: Global Leaders Call for Shared Responsibility at the World Health Summit, Gallup and GPMB Release Landmark Reports on Emotional Wellbeing and Pandemic Preparedness
mehrGermans would value more trustworthy online health information
Gütersloh (ots) - Most people these days look online for answers to questions on health. However, many have doubts on the integrity and quality of the information provided by social media platforms and AI chatbots. The Bertelsmann Stiftung would like to contribute to promoting reliable sources and increasing confidence in digital information on health by means of its ...
mehrIEVA (Independent European Vape Alliance)
WHO must embrace harm reduction at COP11 to truly drive down global smoking rates
Brussels (ots) - As the 11th Conference of the Parties (COP11) to the WHO Framework Convention on Tobacco Control (FCTC) approaches (17–22 November 2025, Geneva), the Independent European Vape Alliance (IEVA) calls on the World Health Organization (WHO) and its member states to finally place harm reduction at the centre of the global tobacco control debate. IEVA ...
mehrLetter of Intent for strategic partnership / Vaccentis and TrueMed join forces to advance cancer vaccine
Zurich (ots) - Vaccentis, a Zurich based biotech company specializing in the development of therapeutic protein-based tumor vaccines, has signed a letter of intent with TrueMed, a leading commercialization partner. Accelerating cancer vaccine against renal cell carcinoma The aim of this letter of intent is to ...
mehrData4Life and EvidNet form strategic partnership to advance federated real-world evidence generation
Seoul, South Korea & Potsdam, Germany (ots) - Data2Evidence meets FeederNet: Joining forces for scalable, standardized, and responsible health research infrastructure Nonprofit digital health organization Data4Life and South Korea’s leading federated research platform EvidNet today announced a strategic ...
mehrFAMAR Group: Dr. Riku Rautsola Appointed New CEO
Athens, Greece (ots/PRNewswire) - After 16 years with FAMAR, including the last 4 years as CEO, Konstantinos Rengis decided to step down from his role for personal reasons, effective September 29, 2025. Kostas is widely recognized for his customer-centric approach, deep knowledge of our industry, and his solution-oriented mindset. During his tenure, he played a pivotal role in successfully guiding the company through ...
mehrAsklepios Kliniken GmbH & Co. KGaA
2Dr. Carl June and Dr. Michel Sadelain are being awarded the Broermann Medical Innovation Award 2025
mehrServier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Suresnes, France (ots/PRNewswire) - - Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company - KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA - Acquisition ...
mehr
12345678910Nächste